Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis

Executive Summary

FDA approved the JAK inhibitor as the first oral medicine for moderate to severe ulcerative colitis, providing Pfizer with fertile new commercial ground for the blockbuster drug.

You may also be interested in...



Sun Outstrips Viatris’ Pentasa Action Date With First ANDA Approval

Sun Pharma has scooped a first ANDA approval for a rival to Takeda’s mesalamine-containing brand Pentasa, with Viatris making clear recently that it was eyeing a first-time generic launch for the gastrointestinal drug.

Pfizer’s Big Bet On Arena Pays Off With First Phase III Win For Etrasimod In UC

The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.

AbbVie Grows Gastrointestinal Business With Rinvoq Approval In UC

Along with Skyrizi’s expected approval in Crohn’s, AbbVie says Rinvoq in ulcerative colitis is key to its Humira sales erosion strategy. It is Rinvoq’s third US supplemental approval since December.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel